Xibrom
Links shared publicly online about this topic
ISTA Pharmaceuticals Announces Positive Results for Xibrom™ Once-Daily
eyedocnews.com — “ISTA Pharmaceuticals, Inc. has announced positive Phase 3 results from a confirmatory clinical trial with Xibrom™ (bromfenac ophthalmic solution) 0.09% QD in the treatment of ocular inflammation and pain after cataract surgery.” View full resource at eyedocnews.com
Most Recently Shared on August 30, 2009 at 10:37 pm By:
Dr. Ari Weitzner Doctor, Ophthalmologist, and Physician
Discuss: ISTA Pharmaceuticals Announces Positive Results for Xibrom: By Dr. Dominique Walton BrooksISTA .. http://bit.ly/14srOS
Xibrom satisfaction and usage data | Monitoring several patients | Drug safety information | MediGuard
mediguard.org — “Xibrom satisfaction and usage data | Monitoring several patients | Drug safety information | MediGuard” View full resource at mediguard.org
Most Recently Shared on July 7, 2011 at 1:17 pm By:
MediGuard.org Health Organization
Real outcomes of 18 #xibrom users tracking now on MediGuard, http://tinyurl.com/44pag8v
InSite Vision Files IND For ISV-101 With The U.S. Food And Drug Administration For The Treatment Of Dry Eye Disease
medicalnewstoday.com — “InSite Vision Incorporated (OTCBB:INSV) announced that it has filed an Investigational New Drug (IND) application for ISV-101 with the U.S. Food and Drug Administration (FDA). ISV-101 is InSite Vi” View full resource at medicalnewstoday.com
Most Recently Shared on January 13, 2011 at 3:05 pm By:
InSite Vision Files IND For ISV-101 With The U.S. Food And Drug Administration For The Treatment Of Dry Eye Disease http://mnt.to/3PWD
InSite Vision Completes Patient Enrollment In ISV-303 Phase 1/2 Clinical Study For Post-Surgical Ocular Pain And Swelling
medicalnewstoday.com — “InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, has announced that patient enrollment was recently completed in the company's Phase 1/2 clinical trial” View full resource at medicalnewstoday.com
Most Recently Shared on January 10, 2011 at 1:05 pm By:
InSite Vision Completes Patient Enrollment In ISV-303 Phase 1/2 Clinical Study For Post-Surgical Ocular Pain And Swelling http://mnt.to/3PMj
InSite Vision Announces Positive Phase 1/2 Results for ISV-303 for the Reduction of Pain and Inflammation after Cataract Surgery - Drugs.com MedNews
drugs.com — “Once-Daily ISV-303 Demonstrates Statistical Significance over Vehicle and Numeric Superiority over Twice-Daily Xibrom InSite Vision s Late Stage Pipeline Now In” View full resource at drugs.com
Most Recently Shared on March 22, 2011 at 2:05 pm By:
Drugs and Devices OW OW Health
InSite Vision Announces Positive Phase 1/2 Results for ISV-303 for the Reduction of Pain and Inflammation ... http://bit.ly/ihw5TV #drug
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Dr. Ari Weitzner
Brooklyn, NY Ophthalmologist; Editor of EyeDocNews; Founder of Share Medical Space
-
MediGuard.org
Live health insights from 2.5+ million users of MediGuard, the easiest way to get safety alerts and recalls for your medicines.
-
MNT Eye Health
The latest eye health news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
